Calidi Biotherapeutics AI Stock Analysis
Want to see CLDI full AI Analyst Report?
Calidi Biotherapeutics (CLDI) AI Stock Analysis
Calidi Biotherapeutics
(NYSE MKT:CLDI)
Calidi Biotherapeutics carries severe investment risk primarily driven by its complete lack of commercial revenue, significant cash drain, and immediate NYSE delisting threats. While promising preclinical trial data and recent debt reductions show fundamental progress, aggressively bearish technical indicators and the constant need for dilutive capital raises currently dominate the stock's overall profile.
Calidi Biotherapeutics (CLDI) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.69M
- Dividend Yield
- ―
- Average Volume (3M)
- 108.65K
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 1.01
- Revenue Growth
- ―
- EPS Growth
- 53.95%
- Country
- US
- Employees
- 29
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Calidi Biotherapeutics Business Overview & Revenue Model
Company Description
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (dono...
How the Company Makes Money
Calidi Biotherapeutics is a clinical-stage biopharmaceutical company and, as such, it generally does not generate meaningful recurring revenue from product sales until a therapy is approved and commercialized. Specific, company-reported revenue break...
Calidi Biotherapeutics Financial Statement Overview
Summary
Calidi generates no commercial revenue and suffers from severe operational cash burn, with free cash flow at negative $17.8 million over the trailing twelve months. Despite commendable debt reductions, the company's small asset base and massive unprofitability pose significant liquidity risks.
Income Statement
15Very NegativeBalance Sheet
35NegativeCash Flow
15Very Negative| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 45.00K | 449.00K |
| Gross Profit | -426.00K | -1.65M | 0 | -1.26M | -229.00K | 355.00K |
| EBITDA | -15.62M | -18.19M | -19.73M | -24.20M | -25.00M | -9.45M |
| Net Income | -17.47M | -19.91M | -22.14M | -29.22M | -25.43M | -10.93M |
Balance Sheet | ||||||
| Total Assets | 7.20M | 8.86M | 14.18M | 10.02M | 2.60M | 3.39M |
| Cash, Cash Equivalents and Short-Term Investments | 4.07M | 5.60M | 9.59M | 2.05M | 372.00K | 2.14M |
| Total Debt | 1.94M | 2.56M | 7.04M | 7.24M | 5.99M | 5.18M |
| Total Liabilities | 4.07M | 5.10M | 12.21M | 18.25M | 53.04M | 26.00M |
| Stockholders Equity | 3.13M | 3.76M | 1.53M | -8.23M | -50.44M | -22.61M |
Cash Flow | ||||||
| Free Cash Flow | -17.81M | -21.41M | -19.71M | -27.57M | -13.64M | -7.98M |
| Operating Cash Flow | -17.75M | -21.29M | -19.69M | -26.98M | -13.21M | -7.77M |
| Investing Cash Flow | -144.00K | -170.00K | -16.00K | -478.00K | -494.00K | -215.00K |
| Financing Cash Flow | 16.81M | 17.46M | 27.36M | 29.04M | 12.09M | 9.81M |
Calidi Biotherapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLDI, the sentiment is Negative. The current price of 0.62 is below the 20-day moving average (MA) of 0.70, below the 50-day MA of 0.96, and below the 200-day MA of 3.73, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 34.94 is Neutral, neither overbought nor oversold. The STOCH value of 27.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLDI.
Calidi Biotherapeutics Risk Analysis
Calidi Biotherapeutics disclosed 85 risk factors in its most recent earnings report. Calidi Biotherapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksCalidi Biotherapeutics Peers Comparison
Overall Rating
- CLDI39Underperform
JAGX37Underperform
Financial Indicators
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CLDI | Calidi Biotherapeutics, Inc. | 0.62 | -23.38 | -97.41% | |
| JAGX | Jaguar Animal Health Inc. | 0.42 | -685.01 | -99.94% | |
| CDIO | Cardio Diagnostics Holdings Inc. | 1.89 | -1.10 | -36.79% |
Calidi Biotherapeutics Corporate Events
Calidi Biotherapeutics Reports Third-Quarter 2026 Financial Results
PositiveCalidi Biotherapeutics reported third-quarter 2026 results on November 13, 2026, including a $3.6 million net loss attributable to common stockholders versus $10.8 million a year earlier; the prior-year figure included a $5.7 million non-cash deemed-...
Calidi Biotherapeutics Addresses NYSE American Compliance Notice
NegativeOn September 21, 2026, Calidi Biotherapeutics received a notification from NYSE American that it was no longer in compliance with the exchange’s continued listing standard requiring at least $4.0 million in stockholders’ equity for companies with mul...
Calidi Biotherapeutics Announces Registered Direct Stock Offering
PositiveOn September 17, 2026, Calidi Biotherapeutics, Inc. entered into a stock purchase agreement with accredited investors and qualified institutional buyers for a registered direct offering of 1,025,640 shares of common stock at $1.17 per share. The offe...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026